Amicus Therapeutics



Migalastat Monotherapy Phase 3 Cardiac Data

January 8, 2015

at the forefront of therapies for rare and orphan diseases

Safe Harbor

This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to business, operations and financial conditions of Amicus including but not limited to preclinical and clinical development of Amicus' candidate drug products, cash runway, and the timing and reporting of results from clinical trials evaluating Amicus' candidate drug products. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "would," "should" and "could," and similar expressions or words, identify forward-looking statements. Although Amicus believes the expectations reflected in such forward-looking statements are based upon reasonable assumptions, there can be no assurance that its expectations will be realized. Actual results could differ materially from those projected in Amicus' forward-looking statements due to numerous known and unknown risks and uncertainties, including the "Risk Factors" described in our Annual Report on Form 10-K for the year ended December 31, 2013. All forward-looking statements are qualified in their entirety by this cautionary statement, and Amicus undertakes no obligation to revise or update this presentation to reflect events or circumstances after the date hereof.

Fabry Disease Overview

Cardiovascular Disease Recognized as Leading Cause of Death in Fabry Patients[1,2]



- Deficiency of lysosomal enzyme α-Gal A leading to GL-3 accumulation
- Heterogeneous (>800 known mutations)
- Symptoms include pain, gastrointestinal problems, angiokeratomas
- Cardiovascular disease, renal failure, stroke are leading causes of morbidity
- Left ventricular hypertrophy is a hallmark of Fabry cardiomyopathy, associated with increased risk of cardiac events and mortality[3]
- Natural history data indicate left ventricular mass increases progressively in untreated patients[4,5]

[1]Mehta 2009, [2]Waldek 2009, [3]Patel 2011, [4]Kampmann 2008, [5]Germain 2013

Amicus Therapeutics

(Previously Reported)

Cardiac Data (LVMi): Phase 3 Study 012

Migalastat Previously Demonstrated Statistically Significant Decrease in LV Mass Index (LVMi) in Subjects Switched from ERT

Left Ventricular Mass Index (LVMi) (g/m^2)* in Phase 3 Study 012 Change from Baseline to Month 18

	Migalastat Baseline Mean (% abnormal) n=33	Migalastat Change from Baseline to M18 (mean, 95%CI) n=31	ERT Baseline Mean (% abnormal) n=16	ERT Change from Baseline to M18 (mean, 95%CI) n=13
Study 012 (Month 18)	95.3 (39%)	-6.6 (-11.0, -2.1)***	92.9 (31%)	-2.0 (-11.0, +7.0)

*Read in blinded manner in centralized lab every 6 months. Normal LVMI: 43-95 (female), 49-115 (male)
**mITT population
***Statistically significant (95% CI does not overlap zero)

Amicus Therapeutics

(Previously Reported)

Cardiac Data (LVMi): Phase 3 Study 012

Reductions in LVMi Observed in Patients Switched from ERT Through Month 18 *





Note: Mean and 95% confidence intervals on change from baseline are plotted

Amicus Therapeutics

(NEW Data)

Cardiac Data (LVMi): Phase 3 Study 011+041

Migalastat Now Shows Statistically Significant Reduction in LVMi in Previously Untreated Patients

Left Ventricular Mass Index (LVMi) (g/m^2)* Change from Baseline to Last Available Time Point		
	Migalastat Baseline Mean (% abnormal) n=42	Migalastat Change from Baseline (mean, 95%CI) n=42
Study 011+041 (Avg 22 Months)**	97.5 (26%)	-8.0 (-13.5, -2.5)***

*Read in blinded manner in centralized lab every 6 months. Normal LVMI: 43-95 (female), 49-115 (male)
**All patients with amenable mutations with baseline and post-baseline values
***Statistically significant (95% CI does not overlap zero)

Amicus Therapeutics

(NEW Data)

Cardiac Data (LVMi): Phase 3 Study 011+041

New Data Also Show Migalastat Has Persistent and Increasing Positive Effect on LVMi Over Longer Periods of Time (Up to 36 Months)



Sample size differences are due to subjects not yet reaching a given timepoint or due to missing Echos

Note: Mean and 95% confidence intervals on change from baseline are plotted

Amicus Therapeutics

Global Regulatory Strategy

Cardiac Effect Strengthens Totality of Clinical Data Supporting Marketing Applications



Amicus Therapeutics

Amicus Therapeutics



Migalastat Monotherapy Phase 3 Cardiac Data

January 8, 2015

at the forefront of therapies for rare and orphan diseases